Reported 1 day ago
In May 2024, Jim Cramer expressed optimism about Mind Medicine Inc. (MNMD), a biotech firm focusing on psychedelic treatments for mental health, believing it could address significant pain and addiction issues. However, despite his support, the stock experienced a 22.97% decline, leading to questions about the viability of his investment advice. While there is potential for MNMD, insights suggest that alternative AI stocks may offer better returns.
Source: YAHOO